US company backs out of Elan deal

A US company today backed out of a €785m deal to buy the primary care business unit and two brand-name drugs from the Elan Corporation.

US company backs out of Elan deal

A US company today backed out of a €785m deal to buy the primary care business unit and two brand-name drugs from the Elan Corporation.

King Pharmaceuticals of Tennessee claimed in a statement that Elan committed “various breaches and misrepresentations” involving the asset purchase agreement signed by the companies on January 30.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited